Toxicity and causes of death
. | Number . |
|---|---|
| Toxicity, day 0 to 20, median | |
| Maximum serum aspartate aminotransferase, μM/s (range) | 56 (21-516) |
| Maximum serum creatinine, μM (range) | 97 (53-362) |
| Maximum total serum bilirubin, μM (range) | 42 (13-188) |
| Toxicity, nonfatal, day 0 to 100, no. of patients | |
| Mucositis, grade 3 | 31 |
| Veno-occlusive disease, grade 4 | 1 |
| Pneumonitis, grade 4 | 1 |
| Bacteremia | 2 |
| Invasive fungal infection | 2 |
| CMV reactivation, 22 seropositive pairs | 12 |
| Fatal toxicity and causes of death, no. of patients | |
| Relapse or progression of malignancy | 12 |
| Idiopathic pneumonia syndrome | 5 |
| Acute GVHD/bacterial sepsis | 1 |
| Cardiac failure due to suspected endocardial fibrosis | 1 |
| Encephalopathy | 1 |
| Chronic GVHD and aspergillosis | 2 |
. | Number . |
|---|---|
| Toxicity, day 0 to 20, median | |
| Maximum serum aspartate aminotransferase, μM/s (range) | 56 (21-516) |
| Maximum serum creatinine, μM (range) | 97 (53-362) |
| Maximum total serum bilirubin, μM (range) | 42 (13-188) |
| Toxicity, nonfatal, day 0 to 100, no. of patients | |
| Mucositis, grade 3 | 31 |
| Veno-occlusive disease, grade 4 | 1 |
| Pneumonitis, grade 4 | 1 |
| Bacteremia | 2 |
| Invasive fungal infection | 2 |
| CMV reactivation, 22 seropositive pairs | 12 |
| Fatal toxicity and causes of death, no. of patients | |
| Relapse or progression of malignancy | 12 |
| Idiopathic pneumonia syndrome | 5 |
| Acute GVHD/bacterial sepsis | 1 |
| Cardiac failure due to suspected endocardial fibrosis | 1 |
| Encephalopathy | 1 |
| Chronic GVHD and aspergillosis | 2 |